Given their potential of limiting AAA progression, many of these agents, including statins, angiotensin-converting enzyme (ACE) inhibitors, antibiotics, beta blockers, and anti-inflammatory agents, are being investigated in clinical trials [40], [41]. Here, ACE is linked to triple-A syndrome.